Pages that link to "Q43094309"

The following pages link to Amelioration of ketamine-induced working memory deficits by dopamine D1 receptor agonists (Q43094309):

Displaying 20 items.

• Has an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia (Q28275290) (← links)
• Inhibition of phosphodiesterase 10A has differential effects on dopamine D1 and D2 receptor modulation of sensorimotor gating (Q28385659) (← links)
• Negative Allosteric Modulators Selective for The NR2B Subtype of The NMDA Receptor Impair Cognition in Multiple Domains (Q30830257) (← links)
• PICK1 Genetic Variation and Cognitive Function in Patients with Schizophrenia (Q33689579) (← links)
• Reviewing the ketamine model for schizophrenia (Q34046060) (← links)
• Relationship between glycine transporter 1 inhibition as measured with positron emission tomography and changes in cognitive performances in nonhuman primates (Q34357077) (← links)
• Role of Thalamic Projection in NMDA Receptor-Induced Disruption of Cortical Slow Oscillation and Short-Term Plasticity (Q34953049) (← links)
• Effects of ketamine on context-processing performance in monkeys: a new animal model of cognitive deficits in schizophrenia (Q37172725) (← links)
• NMDA receptors, cognition and schizophrenia – Testing the validity of the NMDA receptor hypofunction hypothesis (Q37855203) (← links)
• Schizophrenia as a disorder of too little dopamine: implications for symptoms and treatment (Q37862242) (← links)
• Use of translational pharmacodynamic biomarkers in early-phase clinical studies for schizophrenia. (Q38170140) (← links)
• A subanesthetic dose of ketamine in the Rhesus monkey reduces the occurrence of anticipatory saccades (Q38987330) (← links)
• New therapeutic strategies targeting D1-type dopamine receptors for neuropsychiatric disease. (Q39172080) (← links)
• The neurobiology of thought: the groundbreaking discoveries of Patricia Goldman-Rakic 1937-2003. (Q41880359) (← links)
• Reduction of brain kynurenic acid improves cognitive function. (Q42463552) (← links)
• Preclinical evaluation of non-imidazole histamine H3 receptor antagonists in comparison to atypical antipsychotics for the treatment of cognitive deficits associated with schizophrenia. (Q46038979) (← links)
• A proof-of-concept, randomized controlled trial of DAR-0100A, a dopamine-1 receptor agonist, for cognitive enhancement in schizophrenia (Q46330442) (← links)
• Dopamine, psychosis and schizophrenia: the widening gap between basic and clinical neuroscience. (Q47550545) (← links)
• The anaesthetic combination of ketamine/midazolam does not alter the acquisition of spatial and motor tasks in adult mice. (Q48101736) (← links)
• Characterization of PF-6142, a Novel, Non-Catecholamine Dopamine Receptor D1 Agonist, in Murine and Nonhuman Primate Models of Dopaminergic Activation (Q98177426) (← links)